AR098271A1 - 5-HT₂C RECEIVER AGONISTS - Google Patents
5-HT₂C RECEIVER AGONISTSInfo
- Publication number
- AR098271A1 AR098271A1 ARP140104108A ARP140104108A AR098271A1 AR 098271 A1 AR098271 A1 AR 098271A1 AR P140104108 A ARP140104108 A AR P140104108A AR P140104108 A ARP140104108 A AR P140104108A AR 098271 A1 AR098271 A1 AR 098271A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- addiction
- heteroaryl
- cycloalkyl
- alkylene
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 title 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 title 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 abstract 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 abstract 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000001613 Gambling Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019430 Motor disease Diseases 0.000 abstract 1
- 241000208125 Nicotiana Species 0.000 abstract 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036186 satiety Effects 0.000 abstract 1
- 235000019627 satiety Nutrition 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan agonistas del receptor 5-HT₂C (receptores de serotonina). También se proporcionan métodos para controlar el peso, inducir saciedad y reducir el consumo de alimentos, y para prevenir y tratar la obesidad, el aumento de peso inducido por antipsicóticos, la diabetes de tipo 2, síndrome de Prader-Willi, dependencia del. tabaco/nicotina, drogadicción, adicción al alcohol, ludopatía, síndrome de déficit de recompensa y adicción al sexo, trastornos de espectro obsesivo-compulsivo y trastornos del control de impulsos, trastornos del sueño, incontinencia urinaria, trastornos psiquiátricos, enfermedad de Alzheimer, disfunción sexual, disfunción eréctil, epilepsia, trastornos motores, hipertensión, dislipidemia, enfermedad hepática grasa no alcohólica, neuropatías relacionadas con la obesidad y apnea del sueño. Reivindicación 1: Un compuesto seleccionado entre compuestos de fórmula (1), y sus sales, hidratos y solvatos, donde: X se selecciona entre O y S; y R¹ se selecciona entre: alquilo C₁₋₆, cicloalquilo C₃₋₇, (cicloalquil C₃₋₇)-(alquileno C₁₋₆), heteroarilo y heteroaril(alquileno C₁₋₆); cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados entre: alcoxi C₁₋₆, (alcoxi C₁₋₆)carbonilo, alquiltio C₁₋₆, alquilsulfonilo C₁₋₆, ariloxi, halógeno y haloalquilo C₁₋₆.5-HT₂C receptor (serotonin receptor) agonists are provided. Also provided are methods to control weight, induce satiety and reduce food consumption, and to prevent and treat obesity, weight gain induced by antipsychotics, type 2 diabetes, Prader-Willi syndrome, dependence on. tobacco / nicotine, drug addiction, alcohol addiction, gambling, reward deficit syndrome and sex addiction, obsessive-compulsive spectrum disorders and impulse control disorders, sleep disorders, urinary incontinence, psychiatric disorders, Alzheimer's disease, dysfunction sexual, erectile dysfunction, epilepsy, motor disorders, hypertension, dyslipidemia, non-alcoholic fatty liver disease, obesity-related neuropathies and sleep apnea. Claim 1: A compound selected from compounds of formula (1), and their salts, hydrates and solvates, wherein: X is selected from O and S; and R¹ is selected from: C₁₋₆ alkyl, C₃₋₇ cycloalkyl, (C₃₋₇ cycloalkyl) - (C₁₋₆ alkylene), heteroaryl and heteroaryl (C₁₋₆ alkylene); each optionally substituted with one or more substituents selected from: C₁₋₆ alkoxy, (C₁₋₆ alkoxy) carbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, aryloxy, halogen and C₁₋₆ haloalkyl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898678P | 2013-11-01 | 2013-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098271A1 true AR098271A1 (en) | 2016-05-18 |
Family
ID=55809934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104108A AR098271A1 (en) | 2013-11-01 | 2014-11-03 | 5-HT₂C RECEIVER AGONISTS |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR098271A1 (en) |
| TW (1) | TW201605856A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2020212951A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| CN115667217A (en) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | Deuterated tryptamine derivatives and methods of use |
-
2014
- 2014-10-15 TW TW103135712A patent/TW201605856A/en unknown
- 2014-11-03 AR ARP140104108A patent/AR098271A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201605856A (en) | 2016-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001380A (en) | 5-HT2C RECEIVER AGONISTS AND COMPOSITIONS AND METHODS OF USE. | |
| MX2017013902A (en) | 5-HT2C RECEIVER AGONISTS AND COMPOSITIONS AND METHODS OF USE. | |
| AR098271A1 (en) | 5-HT₂C RECEIVER AGONISTS | |
| MX2013006911A (en) | SUB-LINGUAL FILMS. | |
| MX391442B (en) | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE. | |
| PE20141360A1 (en) | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND INDICATIONS FOR THEM. | |
| EP2740037A4 (en) | LEVELING OF WEAR FOR MEMORY DEVICE | |
| PE20091324A1 (en) | SPIRO COMPOUNDS AS ANTAGONISTS OF THE NPY Y5 RECEIVER | |
| EA201291236A1 (en) | NITROGEN HETEROCYCLIC COMPOUNDS APPLICABLE AS PDE10 INHIBITORS | |
| RU2012116003A (en) | MACROCYCLIC INHIBITORS JAK | |
| EA201790395A1 (en) | AMINOTRIAZIN DERIVATIVES SUITABLE FOR USING AS TANK-BINDING KINASE INHIBITORS | |
| MX2016008624A (en) | Serine/threonine kinase inhibitors. | |
| UY34444A (en) | METHODS TO INHIBIT TUMOR GROWTH ANTAGONIZING THE IL-6 RECEIVER | |
| UY34486A (en) | ANTIBODIES TARGETED AT THE RECEPTOR OF EPIDERMAL GROWTH FACTOR 3 (HER3) TARGETED AGAINST DOMAIN II OF HER3 | |
| PH12014502754A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| EA200701588A1 (en) | METHODS OF OBTAINING SUBSTITUTED PHYLPYRAZOLMOCHEVINS | |
| EA201101241A1 (en) | TREATMENT OF LEUKEMIA AND CHRONIC MYELOPROLIFERATIVE DISEASES BY ERP3 Antibodies | |
| CL2016001348A1 (en) | Crystalline form of hydrochloride of (s) - (2- (6-chloro-7-methyl-1h-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- ( 2h-1,2,3-triazol-2-yl) phenyl) methanone; pharmaceutical composition comprising it; and its use for the treatment or prevention of sleep disorders, such as dysomnias, parasomnias, among others. | |
| SMT201500086B (en) | Use of nifuratel for the treatment of infections caused by the atopobium species | |
| CL2008002118A1 (en) | Method for the production of an equine embryo of selected sex by intracytoplasmic sperm injection using equine sperm selected by sex. | |
| AR101264A1 (en) | PIRIDONAS AS HERBICIDES | |
| FR3027051B1 (en) | DEVICE FOR COMPENSATING THE OPERATING GAMES OF AN ENGINE. | |
| CR9733A (en) | DERIVATIVES OF AZINIL-3-SULFONYLINDAZOL AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6 | |
| PE20190803A1 (en) | 1-ARYLNAFTIRIDIN-3-CARBOXAMIDES 7-SUBSTITUTED AND THEIR USE | |
| EP3501460A4 (en) | CONDOM FOR PATIENT SUFFERING FROM ERECTILE DYSFUNCTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |